Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Most Observers Still Want More Detailed Data From Urothelial Cancer Study

 
• By Alaric DeArment
  
Seagen/Astellas announced topline results from the Phase Ib/II study of Padcev/Keytruda in urothelial cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business